Drugdu.com (“Ddu”) will attend INTERPHEX JAPAN

June 21, 2017  Source: Ddu 496

INTERPHEX JAPAN will be held in Big Sight, Tokyo from June 28th - 30th. As the leading global pharmaceutical and medical device B2B online platform, Ddu will attend the fair with products from high priority members.

With more than 1,830 exhibitors and 63,000 visitors, INTERPHEX JAPAN is the world's leading and firmly established B2B trade show specialized in Pharmaceutical R&D and Manufacturing.

As the world's second largest pharmaceutical market, Japan has a strong demand for pharmaceutical products, which generates huge potential for the Japanese pharmaceutical market. Due to the short distance between China and Japan, INTERPHEX JAPAN will be a great opportunity for Chinese suppliers to explore the Japanese pharmaceutical market.

Ddu, the leading global pharmaceuticals and medical devices B2B online platform, will attend INTERPHEX JAPAN. Ddu will promote high priority members as well as their products during the exhibition to help users explore the Japanese market.

Ddu’s fast matching service system will be used during the fair. Buyers and suppliers will be matched automatically in the database which includes 100,000 companies and 1,000,000 products. Ddu explains that the system will match and recommend partners to users after the product name and target area are filled in, so that 40% of business efficiency will be improved.

What’s more, sharing of sourcing requests in different exhibitions is another highlight of this exhibition. This service was applied in CPhI Shanghai and attracted numerous visitors’ interests. It is said that this sharing service of sourcing request will be extended to Japan. Sourcing requests collected from CPhI Shanghai will be shown via the screen in Ddu’s booth. QR codes will be put in prominent places of the exhibition. Buyers could scan the QR code to release sourcing requests which will be shared in CEEP Shanghai.

See you at Booth E15-001 from June 28th to 30th.

 

 

 

By editor
Share: 

your submission has already been received.

OK

Subscribe

Please enter a valid Email address!

Submit

The most relevant industry news & insight will be sent to you every two weeks.